EUROPEAN DRUG REPORT 2016 — HIGHLIGHTS

EMCDDA highlights new health risks as products and patterns of use change

Europe’s drug market remains resilient, says the EU drugs agency (EMCDDA) today as it launches in Lisbon its European Drug Report 2016: Trends and Developments,

News by year

Media support

To schedule interviews, obtain informed comment, request written contributions or receive the latest news on the agency, please contact our media relations sector:

Kathy Robertson
Head of sector
Media relations and marketing
Tel: (351) 211 21 02 00/32
Fax: (351) 211 21 03 80

Preventing opioid overdose deaths with take-home naloxone

Upcoming ISCTE-IUL–EMCDDA Summer School: 27 June–8 July 2016

Registration opens for fifth European drugs summer school

This year the University Institute of Lisbon (ISCTE-IUL) and the EMCDDA will be hosting the fifth European drugs summer school (EDSS) from 27 June to 8 July. Registration opens today...

News by year

Media support

To schedule interviews, obtain informed comment, request written contributions or receive the latest news on the agency, please contact our media relations sector:

Kathy Robertson
Head of sector
Media relations and marketing
Tel: (351) 211 21 02 00/32
Fax: (351) 211 21 03 80

Comorbidity of substance use and mental disorders in Europe

Comorbidity of substance use and mental disorders in Europe

New EMCDDA report explores combined mental health and substance use disorders

The co-existence of mental illness and psychoactive drug or other substance use problems — otherwise known as ‘comorbidity’ or ‘dual diagnosis’ — is an issue which has been on the radar of the EU drugs agency (EMCDDA) for over a decade (1).

News by year

Media support

To schedule interviews, obtain informed comment, request written contributions or receive the latest news on the agency, please contact our media relations sector:

Kathy Robertson
Head of sector
Media relations and marketing
Tel: (351) 211 21 02 00/32
Fax: (351) 211 21 03 80

EMCDDA hosts fourth annual Reitox week

Over 40 countries attend 2015 Reitox week in Lisbon

Representatives of candidate, potential candidate and neighbouring countries of the EU are joining members of the EMCDDA’s Reitox network in Lisbon today for the kick-off of the agency’s fourth Reitox week.

News by year

Media support

To schedule interviews, obtain informed comment, request written contributions or receive the latest news on the agency, please contact our media relations sector:

Kathy Robertson
Head of sector
Media relations and marketing
Tel: (351) 211 21 02 00/32
Fax: (351) 211 21 03 80

EMCDDA co-hosts ‘Testing the waters 2015’

The EU drugs agency (EMCDDA) is co-hosting next week in Ascona, Switzerland, the second international conference on wastewater analysis: ‘Testing the waters 2015’.

News by year

Media support

To schedule interviews, obtain informed comment, request written contributions or receive the latest news on the agency, please contact our media relations sector:

Kathy Robertson
Head of sector
Media relations and marketing
Tel: (351) 211 21 02 00/32
Fax: (351) 211 21 03 80

Events

Meeting on the risk assessment of seven new psychoactive substances

The extended Scientific Committee of the EMCDDA met on 7–8 November 2017 to examine the risk assessment by the EMCDDA on AB-CHMINACA, ADB-CHIMNACA, 5F-MDMB-PINACA, CUMYL-4CN-BINACA, 4-fluoroisobutyrylfentanyl, tetrahydrofuranylfentanyl, and carfentanil.

Events

Meeting on the risk assessment of the new psychoactive substance furanylfentanyl

The extended Scientific Committee of the EMCDDA met on 23 May 2017 to examine the risk assessment by the EMCDDA on furanylfentanyl.

EMCDDA Document library

Council Implementing Decision (EU) 2017/2170 of 15 November 2017 on subjecting N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide (furanylfentanyl) to control measures

This is the implementation decision of the Council of the EU, based on a proposal from the European Commission, was adopted in the final stage of the three-step legal procedure designed to respond to new psychoactive substances (NPS) that may pose public health and social threats. The substance concerned is furanylfentanyl which is a synthetic opioid.

Loading